IBS-C薬の北米市場2020-2227

◆英語タイトル:NORTH AMERICA IBS-C DRUG MARKET FORECAST 2020-2028
◆商品コード:INK20MY278
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年2月
◆ページ数:165
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGS The North America IBS-C drug market is anticipated to register a CAGR of 8.68% over the projected period, 2020-2028. The region of North America has the most developed healthcare systems and medical devices industry in the world. The government agencies, together with private medical firms, are providing the best medical facilities to patients from all over the world. The drug market is continuously growing in the region, owing to federal government initiatives to improve the healthcare sector by providing the latest technological support and advanced medical treatments.

MARKET INSIGHTS
The IBS-C drug market of North America is segregated into the countries of the US and Canada for further surveying the growth in the region. Canada’s statistics and patient conditions are the same as that of the US. The reason for the growing number of Irritable Bowel Syndrome (IBS) patients in Canada is patients suffering from chronic pain seek analgesics, mostly opioids, to get rid of non-cancer pains and other forms. It was estimated that in 2019 health spending will account for 11.6% of Canada’s GDP. Canada’s health expenditure per person in 2018 was similar to that of Australia, the Netherlands, and France. The prevalence rates of IBS in Canada, which is around 5 million, is one of the highest in the world. IBS is universally known to affect more women than men, and there are medications prescribed specifically for women. The ratio for IBS patients is seven females to two males in Canada. Many drugs are suggested apart from a lifestyle change, dietary intake, and psychological counseling for treating IBS patients. Despite the decreasing average selling prices, a rise in the number of treatments, the prevalence of GI disorders in the growing population, is boosting the growth of this market.

COMPETITIVE INSIGHTS
Abbott Laboratories, Astellas Pharma US, Inc., Ardelyx, Synthetic Biologics, Catalent Pharma Solutions, etc. are some of the major companies functioning in the market.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
3.2.2. IBS CAN BE A HERITABILITY ISSUE
3.2.3. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
3.3. KEY RESTRAINTS
3.3.1. STRICT FDA REGULATIONS
3.3.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK
5. MARKET BY PRESCRIPTION TYPE
5.1. PRESCRIBED
5.1.1. BRANDED
5.1.2. GENERIC
5.2. OVER THE COUNTER
6. MARKET BY DRUG TYPE
6.1. LUBIPROSTONE
6.2. LINACLOTIDE
6.3. STIMULANT LAXATIVES
6.3.1. BISACODYL
6.3.2. SENNA
6.4. OSMOTIC LAXATIVES
6.4.1. LACTULOSE
6.4.2. POLYETHYLENE GLYCOL
6.5. OTHER DRUG TYPES
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPANY PROFILES
8.1. CATALENT PHARMACEUTICALS SOLUTIONS
8.2. ABBOTT LABORATORIES
8.3. NOVARTIS PHARMA AG
8.4. ASTELLAS PHARMACEUTICALS
8.5. ARDELYX, INC.
8.6. SYNTHETIC BIOLOGICS, INC.
8.7. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
8.8. BAMA-GEVE, SLU
8.9. FERRING BV
8.10. IRONWOOD PHARMACEUTICALS, INC.
8.11. SALIX PHARMACEUTICALS LTD.
8.12. NORGINE B.V.
8.13. PROMETHEUS LABORATORIES, INC.
8.14. ALBIREO PHARMA, INC.
8.15. YUHAN CORP.
8.16. ASTRAZENECA PLC
8.17. THE MENARINI GROUP
8.18. ONO PHARMACEUTICAL CO. LTD.
8.19. ACTAVIS NORDIC A/S

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – IBS-C DRUG
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIPTION TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 5: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIBED, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: NORTH AMERICA IBS-C DRUG MARKET, BY PRESCRIBED, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 7: PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 8: NORTH AMERICA IBS-C DRUG MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: NORTH AMERICA IBS-C DRUG MARKET, BY DRUG TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: PRODUCT PROFILE (LUBIPROSTONE)
TABLE 11: PRODUCT PROFILE (LINACLOTIDE)
TABLE 12: NORTH AMERICA IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: NORTH AMERICA IBS-C DRUG MARKET, BY STIMULANT LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: PRODUCT PROFILE (BISACODYL)
TABLE 15: PRODUCT PROFILE (SENNA)
TABLE 16: NORTH AMERICA IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: NORTH AMERICA IBS-C DRUG MARKET, BY OSMOTIC LAXATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: PRODUCT PROFILE (LACTULOSE)
TABLE 19: PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 20: PRODUCT PROFILE (PSYLLIUM)
TABLE 21: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 22: NORTH AMERICA IBS-C DRUG MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
LIST OF FIGURES
FIGURE 1: DRUGS PULLED OFF FROM THE MARKET
FIGURE 2: KEY INVESTMENT INSIGHTS
FIGURE 3: PORTER’S FIVE FORCE ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: NORTH AMERICA IBS-C DRUG MARKET, GROWTH POTENTIAL, BY PRESCRIPTION TYPE, IN 2019
FIGURE 7: NORTH AMERICA IBS-C DRUG MARKET, PRESCRIBED, 2020-2028 (IN $ MILLION)
FIGURE 8: NORTH AMERICA IBS-C DRUG MARKET, BRANDED, 2020-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA IBS-C DRUG MARKET, GENERIC, 2020-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA IBS-C DRUG MARKET, OVER THE COUNTER, 2020-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA IBS-C DRUG MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2019
FIGURE 12: NORTH AMERICA IBS-C DRUG MARKET, LUBIPROSTONE, 2020-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA IBS-C DRUG MARKET, LINACLOTIDE, 2020-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA IBS-C DRUG MARKET, STIMULANT LAXATIVES, 2020-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA IBS-C DRUG MARKET, SENNA, 2020-2028 (IN $ MILLION)
FIGURE 17: NORTH AMERICA IBS-C DRUG MARKET, OSMOTIC LAXATIVES, 2020-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA IBS-C DRUG MARKET, BISACODYL, 2020-2028 (IN $ MILLION)
FIGURE 19: NORTH AMERICA IBS-C DRUG MARKET, POLYETHYLENE GLYCOL, 2020-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA IBS-C DRUG MARKET, OTHER DRUG TYPES, 2020 -2028 (IN $ MILLION)
FIGURE 21: NORTH AMERICA IBS-C DRUG MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 22: UNITED STATES IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)
FIGURE 23: CANADA IBS-C DRUG MARKET, 2020-2028 (IN $ MILLION)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[IBS-C薬の北米市場2020-2227]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆